China NMPA Drug Inspection - Guangxi Guanfeng Group Guigang Pharmaceutical Co., Ltd. - Scutellaria baicalensis capsules
China NMPA drug inspection for Guangxi Guanfeng Group Guigang Pharmaceutical Co., Ltd. published December 01, 2017. Drug: Scutellaria baicalensis capsules. This document, the "Ningxia Drug Quality Sampling Inspection Information Announcement (No. 14, 2017)," was published by
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Guangxi Guanfeng Group Guigang Pharmaceutical Co., Ltd. published December 01, 2017. Drug: Scutellaria baicalensis capsules. This document, the "Ningxia Drug Quality Sampling Inspection Information Announcement (No. 14, 2017)," was published by
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox